Skip to main content

Table 4 Applied dosages and dose modifications of chemotherapy

From: Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

Treatment and patients

Mean dosage

Mean number of cycles

Patients with dose reduction

Patients with delays

Mean delay (range)

Break-off current therapy line

 

%

N

N (%)

N

Days

%

1st line

      

Platinum (n = 248)

96.1

3.9

47 (19.0)*

101

15 (3–52)

57.7

For combination therapy: combined cytotoxic drug (n = 248)

84.1

3.9

146 (58.9)*

101

15 (3–52)

57.7

Monotherapy (n = 60)

82.9

2.2

31 (51.7)

13

14 (7–28)

91.6

2nd line

      

Monotherapy (n = 117)

95.4

3.2

20 (17.0)

26

15 (4–49)

77.7

EGFR-TKI (n = 41)

**

4.4

**

**

**

NA

Platinum-basedcombination (n = 18)

NA

3.6

14 (77.8)

8

18 (4–31)

55.6

3rd line

      

Monotherapy (n = 49)

95.2

2.9

8 (16.3)

9

12 (7–24)

81.6

EGFR-TKI (n = 36)

**

3.4

**

**

**

NA

Platinum-basedcombination (n = 7)

NA

3.3

4 (57.1)

3

12 (7–21)

71.4

  1. Patients who entered clinical studies were excluded. EGFR TKI, tyrosine kinase inhibitor targeting the epidermal growth factor receptor. NA, not applicable.
  2. *36 patients (14.5%) received a dose reduction of platinum and combined cytotoxic drug.
  3. **no reliable data available.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us